Celldex Therapeutics CLDX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -35,688.5%-32,815pp | -18,587.7%-15,809pp | -9,855.4%-7,984pp | -4,053.7%-1,936pp | -2,873.5%-194pp | |
| Net margin | -32,753.6%-30,388pp | -16,737.2%-14,488pp | -8,635.8%-7,091pp | -3,446.9%-1,637pp | -2,366.1%+19.9pp | |
| EBITDA margin | -35,299.7%-32,469pp | -18,369.1%-15,635pp | -9,725.3%-7,885pp | -3,995.9%-1,916pp | -2,830.3%-201pp | |
| Free cash flow margin | -26,125.8%-23,832pp | -13,820.1%-11,545pp | -6,987.3%-5,387pp | -3,254.8%-1,774pp | -2,293.3%-302pp | |
| Returns | ||||||
| Return on equity | -48.9%-25.7pp | -40.6%-13.8pp | -32.4%-2.6pp | -27.2%+0.4pp | -23.2%+2.2pp | |
| Return on assets | -45.4%-23.1pp | -37.6%-12.5pp | -30.5%-2.6pp | -26%+0.3pp | -22.2%+2.0pp | |
| Return on invested capital | -55.6%-24.9pp | -47%-12.1pp | -38.9%-0.8pp | -33.3%+0.9pp | -30.7%+2.6pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 8.9×-12.7× | 10.5×-8.4× | 13×-11.3× | 19.7×-9.7× | 21.7×-10.1× | |
| Quick ratio | 8.9×-12.7× | 10.5×-8.4× | 13×-11.3× | 19.7×-9.7× | 21.7×-10.1× | |
| Cash ratio | 0.7×+0.2× | 0.6×-0.2× | 0.8×-0.4× | 0.7×-0.8× | 0.5×-3.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $6.85-35.3% | $7.94-31.6% | $9.01-24.0% | $9.87-19.9% | $10.59-25.7% | |
| Valuation | ||||||
| Market capitalization | $2.11B+75.2% | $1.8B+7.6% | $1.72B-23.8% | $1.44B-41.1% | $1.2B-56.3% | |
| Enterprise value | $2.08B+74.4% | $1.78B+7.6% | $1.68B-24.1% | $1.42B-40.9% | $1.19B-55.0% | |
| Price / sales | 2,438.2×+2,279× | 1,167.4×+929× | 660.7×+435× | 248.2×-45.6× | 159.4×-295× | |
| Price / book | 4.6×+2.9× | 3.4×+1.2× | 2.9×0.0× | 2.2×-0.8× | 1.7×-1.6× | |
| EV / sales | 2,399.1×+2,242× | 1,150.2×+915× | 647.9×+425× | 244.8×-44.2× | 157.6×-278× | |
| Free cash flow yield | -10.7%+3.7pp | -11.8%-2.3pp | -10.6%-3.5pp | -13.1%-8.1pp | -14.4%-10.0pp | |
| Earnings yield | -13.4%+1.4pp | -14.3%-4.9pp | -13.1%-6.2pp | -13.9%-7.7pp | -14.8%-9.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Celldex Therapeutics's ratios come from?
- Every ratio is computed from Celldex Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
